Drug intelligence / Profile preview

2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is a small molecule identified as a highly potent and selective inhibitor of aldo-keto reductase AKR1C3, an enzyme also known as type 5 17-β-hydroxysteroid dehydrogenase. Research indicates its potential as a therapeutic agent, particularly in the context of breast and prostate cancer, where AKR1C3 is a target of interest. Structure-activity relationship studies have been conducted to understand its inhibitory properties.

Targets

AKR1C3 (Aldo-keto reductase family 1 member C3)

Beyond the preview

Go deeper on 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid.

Explore the full profile